Celldex Therapeutics, Inc. (CLDX) stock
Close on Nov 12, 2026Market cap $2.24BP/E –Yield –
Celldex Therapeutics, Inc. saw revenue fall 93.9% to $158.00K over the twelve months to Sep 30, 2026. Free cash flow was -$259.74M. At the latest close the market valued the company at $2.24B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.24B
- P/E ratio
- –
- Price to sales
- 14180.00
- Price to book
- 3.45
- Dividend yield
- –
- Free cash flow yield
- -11.59%
Fundamentals
- Revenue
- $158.00K
- Net income
- -$309.06M
- EPS, diluted
- -$4.30
- Free cash flow
- -$259.74M
- Book value per share
- $8.27
- Diluted shares
- 79M
Trading
- Next earnings
- Feb 24, 2027 (estimated, after the close)
- Previous close
- $30.15
- Open
- $29.72
- Day's range
- $28.46 – $30.01
- Volume
- 867,096
- Average volume (20 days)
- 981,709
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 1.32
- 52-week range
- $22.33 – $45.14
- RSI (14 days)
- 42.0
- Volatility (1 year)
- 52.4%
- Relative volume
- 0.70×
- WACC
- 11.5%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLDX | S&P 500 | Difference | CLDX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.1% | -2.7% | −0.4 pts | ||
| 3 months | -36.4% | -1.7% | −34.7 pts | ||
| Year to date | +5.0% | +11.9% | −6.9 pts | ||
| 1 year | +17.6% | +12.0% | +5.7 pts | ||
| 3 years | +5.9% | +78.2% | −72.3 pts | +1.9% | +21.2% |
| 5 years | -32.0% | +73.2% | −105.3 pts | -7.4% | +11.6% |
| 10 years | -56.0% | +309.6% | −365.6 pts | -7.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Celldex Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- News
- News
About Celldex Therapeutics
In Vitro & In Vivo Diagnostic Substances
Celldex Therapeutics is a biopharmaceutical company that investigates mast cell biology and develops therapeutic antibody treatments. Its product pipeline consists of monoclonal and bispecific antibodies designed to treat severe inflammatory, allergic, and autoimmune conditions. The company's lead drug candidate is barzolvolimab, a monoclonal antibody that inhibits the KIT receptor to reduce mast cell activity across multiple skin disorders. It also develops CDX-622, a bispecific antibody candidate targeting inflammatory pathways. Celldex Therapeutics aims to serve patients suffering from severe mast cell-mediated diseases, including chronic spontaneous urticaria, chronic inducible urticaria, prurigo nodularis, and atopic dermatitis.
Company profile, executives and historyCelldex Therapeutics stock: common questions
What is Celldex Therapeutics's stock price?
CLDX closed at $28.53 on Nov 12, 2026, down 5.37% on the day. Over the past 52 weeks it traded between $22.33 and $45.14.
What is Celldex Therapeutics's market cap?
Celldex Therapeutics was worth $2.24B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CLDX's P/E ratio?
Celldex Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.30), so it has no meaningful P/E ratio.
How much revenue does Celldex Therapeutics make?
Celldex Therapeutics reported revenue of $158.00K for the twelve months to Sep 30, 2026, down 93.9% from a year earlier.
Does Celldex Therapeutics pay a dividend?
No. Celldex Therapeutics has not paid a cash dividend over the last twelve months.
When does Celldex Therapeutics report earnings next?
Celldex Therapeutics is expected to report Q4 FY2026 results on Feb 24, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CLDX stock performed over the past year?
Including dividends, CLDX returned +17.6% over the past year, against +12.0% for the S&P 500.
How many CLDX shares are sold short?
10M shares were sold short at the latest FINRA report, 12.71% of the float, or 10.3 days of average trading volume.
Who are Celldex Therapeutics's competitors?
Companies most similar to Celldex Therapeutics by business, industry and size include AVTX, ABPO, ARTV, PVCT, IMA.
See a number that looks wrong?